Original Articles
Vol. 1 No. 2 (2022)
Circulating albumin-to-fibrinogen ratio may be a risk indicator for venous thromboembolism: findings from a population-based prospective cohort study
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Received: 5 May 2022
Accepted: 1 June 2022
Accepted: 1 June 2022
1164
Views
257
Downloads
Authors
Circulating albumin and fibrinogen levels, commonly considered as inflammatory markers, have been shown to be associated with venous thromboembolism (VTE) risk. Circulating albumin-to-fibrinogen ratio (AFR) has been proposed as a novel inflammatory biomarker, but its association with VTE risk has not been investigated. We aimed to assess the prospective association of AFR with VTE risk. Circulating albumin and fibrinogen levels were measured at baseline in 2,284 men aged 42-61 years. Hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated. During a median follow-up of 27.0 years, 156 VTE cases were recorded. In analysis adjusted for established risk factors, the HR (95% CI) for VTE comparing extreme tertiles of AFR was 1.53 (1.02-2.32), which remained similar on further adjustment for prevalent cancer, 1.52 (1.01-2.30). The associations of circulating albumin or fibrinogen with VTE risk were modest. Circulating AFR may be a stronger risk indicator for VTE compared with albumin or fibrinogen alone.
Downloads
Download data is not yet available.
Citations
Heit JA. The epidemiology of venous thromboembolism in the community. Arterioscler Thromb Vasc Biol 2008;28:370-2. DOI: https://doi.org/10.1161/ATVBAHA.108.162545
Heit JA. Epidemiology of venous thromboembolism. Nat Rev Cardiol 2015;12:464-74. DOI: https://doi.org/10.1038/nrcardio.2015.83
Cushman M. Epidemiology and risk factors for venous thrombosis. Semin Hematol 2007;44:62-9. DOI: https://doi.org/10.1053/j.seminhematol.2007.02.004
Rosendaal FR. Risk factors for venous thrombotic disease. Thromb Haemost 1999;82:610-9. DOI: https://doi.org/10.1055/s-0037-1615887
Fox EA, Kahn SR. The relationship between inflammation and venous thrombosis. A systematic review of clinical studies. Thromb Haemost 2005;94:362-5. DOI: https://doi.org/10.1160/TH05-04-0266
Kunutsor SK, Sameul S, Blom AW, et al. Serum C-reactive protein increases the risk of venous thromboembolism: A prospective study and meta-analysis of published prospective evidence Eur J Epidemiol 2017 32:657-67. DOI: https://doi.org/10.1007/s10654-017-0277-4
Kunutsor SK, Seidu S, Katechia DT, Laukkanen JA. Inverse association between serum albumin and future risk of venous thromboembolism: interrelationship with high sensitivity C-reactive protein. Ann Med 2018:1-9. DOI: https://doi.org/10.1080/07853890.2018.1441537
Klovaite J, Nordestgaard BG, Tybjaerg-Hansen A, Benn M. Elevated fibrinogen levels are associated with risk of pulmonary embolism, but not with deep venous thrombosis. Am J Respir Crit Care Med 2013;187:286-93. DOI: https://doi.org/10.1164/rccm.201207-1232OC
Chi G, Gibson CM, Liu Y, et al. Inverse relationship of serum albumin to the risk of venous thromboembolism among acutely ill hospitalized patients: Analysis from the APEX trial. Am J Hematol 2019;94:21-8. DOI: https://doi.org/10.1002/ajh.25296
Lin C, Chen Y, Chen B, et al. D-Dimer Combined with Fibrinogen Predicts the Risk of Venous Thrombosis in Fracture Patients. Emerg Med Int 2020;2020:1930405. DOI: https://doi.org/10.1155/2020/1930405
Wang J, Xi H, Zhang K, et al. Circulating C-Reactive Protein to Prealbumin Ratio and Prealbumin to Fibrinogen Ratio are Two Promising Inflammatory Markers Associated with Disease Activity in Rheumatoid Arthritis. Clin Lab 2020;66. DOI: https://doi.org/10.7754/Clin.Lab.2019.190833
Simera I, Moher D, Hoey J, et al. A catalogue of reporting guidelines for health research. Eur J Clin Invest 2010;40:35-53. DOI: https://doi.org/10.1111/j.1365-2362.2009.02234.x
Salonen JT. Is there a continuing need for longitudinal epidemiologic research? The Kuopio Ischaemic Heart Disease Risk Factor Study. Ann Clin Res 1988;20:46-50.
Kunutsor SK, Khan H, Laukkanen JA. Serum albumin concentration and incident type 2 diabetes risk: new findings from a population-based cohort study. Diabetologia 2015;58:961-7. DOI: https://doi.org/10.1007/s00125-015-3520-0
Liu Z, Mi J. Serum Albumin and Circulating Metabolites and Risk of Venous Thromboembolism: A Two-Sample Mendelian Randomization Study. Front Nutr 2021;8:712600. DOI: https://doi.org/10.3389/fnut.2021.712600
Folsom AR, Lutsey PL, Heckbert SR, Cushman M. Serum albumin and risk of venous thromboembolism. Thromb Haemost 2010;104:100-4. DOI: https://doi.org/10.1160/TH09-12-0856
Shaper AG, Wannamethee SG, Whincup PH. Serum albumin and risk of stroke, coronary heart disease, and mortality: the role of cigarette smoking. J Clin Epidemiol 2004;57:195-202. DOI: https://doi.org/10.1016/j.jclinepi.2003.07.001
Smith EB. Fibrinogen, fibrin and the arterial wall. Eur Heart J 1995;16A:11-4. DOI: https://doi.org/10.1093/eurheartj/16.suppl_A.11
Lip GY, Lowe GD. Fibrin D-dimer: a useful clinical marker of thrombogenesis? Clin Sci (Lond) 1995;89:205-14. DOI: https://doi.org/10.1042/cs0890205
How to Cite
1.
Kunutsor SK, Kurl S, Voutilainen A, Laukkanen J. Circulating albumin-to-fibrinogen ratio may be a risk indicator for venous thromboembolism: findings from a population-based prospective cohort study. Bleeding Thromb Vascul Biol [Internet]. 2022 Jul. 14 [cited 2025 Nov. 10];1(2). Available from: https://www.btvb.org/btvb/article/view/36
Copyright (c) 2022 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Share
Similar Articles
- CS07 | Endothelial dysfunction and impaired angiogenesis in Hermansky-Pudlak syndrome (HPS) type 1: studies with endothelial colony forming cells , Bleeding, Thrombosis and Vascular Biology: Special issues
- CO31 | Immune system profiling in FVIII-treated and emicizumab-treated pediatric HA patients , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
- Pantep Angchaisuksiri, Wolfram Ruf, Jeffrey Weitz, Sam Schulman, Guy A. Young, A commitment to global collaboration, welcoming international participation and advancing science for the benefit of patients , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. 2 (2025)
- Coenraad H. Hemker, The clinical usefulness of measuring thrombin generation , Bleeding, Thrombosis and Vascular Biology: Vol. 2 No. 1 (2023)
- Daniela Poli, Riccardo Tartaglia, Doris Barcellona , Paolo Bucciarelli , Antonio Ciampa, Elvira Grandone, Giuseppe Malcangi, Giuseppe Rescigno, Vincenzo Toschi, Sophie Testa, Alessandro Squizzato, Attitude to clinical research among health professionals affiliated with the Italian Federation of Centers for the Diagnosis of Thrombotic Disorders and the Surveillance of the Antithrombotic Therapies (FCSA) , Bleeding, Thrombosis and Vascular Biology: Vol. 2 No. 1 (2023)
Previous
191-195 of 195
You may also start an advanced similarity search for this article.
